Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125203182 | 12520318 | 2 | F | 20160503 | 20160517 | 20160701 | 20160831 | EXP | GB-MHRA-ADR-23472066 | GB-ALVOGEN-2016-ALVOGEN-025517 | ALVOGEN | 62.00 | YR | F | Y | 95.25000 | KG | 20160831 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125203182 | 12520318 | 1 | PS | CLINDAMYCIN | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | Oral | 1 DF, 3X/DAY | Y | 62800 | CAPSULE, HARD | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125203182 | 12520318 | 1 | Bacterial infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125203182 | 12520318 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125203182 | 12520318 | Erythema | |
| 125203182 | 12520318 | Lymph node pain | |
| 125203182 | 12520318 | Swelling face |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125203182 | 12520318 | 1 | 20160503 | 20160504 | 0 |